dc.contributor
Institut Català de la Salut
dc.contributor
[Vidaur L] Intensive Care Unit, Donostia University Hospital, Donostia-San Sebastian, Spain. Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Microbiology Department, San Sebastian, Spain. Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. [Azkarate I, Salas E] Intensive Care Unit, Donostia University Hospital, Donostia-San Sebastian, Spain. [Ansa I] Department of Microbiology, Donostia University Hospital-Biogipuzkoa Health Research Institute, San Sebastian, Spain. [Vicente D] Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Microbiology Department, San Sebastian, Spain. Department of Microbiology, Donostia University Hospital-Biogipuzkoa Health Research Institute, San Sebastian, Spain. [Rello J] Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Grup de Recerca Clínica/Innovació en la Pneumònia i Sèpsia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. UR-UM103 IMAGINE, University of Montpellier, Division of Anesthesia Critical Care Pain and Emergency Medicine, Nîmes University Hospital, Montpellier, France
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Vidaur, Loreto
dc.contributor.author
Azkarate, Izaskun
dc.contributor.author
Salas, Estibaliz
dc.contributor.author
Ansa Isasa, Iñigo
dc.contributor.author
Vicente, Diego
dc.contributor.author
Rello, Jordi
dc.date.accessioned
2025-11-06T10:13:06Z
dc.date.available
2025-11-06T10:13:06Z
dc.date.issued
2025-11-05T13:26:38Z
dc.date.issued
2025-11-05T13:26:38Z
dc.identifier
Vidaur L, Azkarate I, Salas E, Ansa I, Vicente D, Rello J, et al. Severe invasive Streptococcus pyogenes infections: A 15-year observational study with molecular characterization of isolates among intensive care adults. J Intensive Med. 2025 Oct;5(4):336–43.
dc.identifier
http://hdl.handle.net/11351/14024
dc.identifier
10.1016/j.jointm.2025.06.001
dc.identifier.uri
http://hdl.handle.net/11351/14024
dc.description.abstract
Antimicrobial stewardship; Clindamycin; Mortality
dc.description.abstract
Administració antimicrobiana; Clindamicina; Mortalitat
dc.description.abstract
Administración antimicrobiana; Clindamicina; Mortalidad
dc.description.abstract
Background
Improving outcomes among patients with invasive group A Streptococcus pyogenes (iGAS) infections is an unmet clinical need. The main objective of this study was to analyze epidemiological and outcome differences in adults admitted to the intensive care unit (ICU) with iGAS infection over a 15-year period and to evaluate the impact of M1uk isolates and clindamycin optimization on patient outcomes.
Methods
This was a single-center observational study conducted at the ICU of Donostia University Hospital, located in Donostia, Spain. The recruitment of all consecutive adult patients admitted to the ICU by iGAS was carried out from January 2010 to May 2024 and divided into three periods: pre-pandemic (January 2010–2019), pandemic (2020–2021), and post-pandemic (May 2022–2024). The main outcome variables were ICU length of stay, hospital length of stay, and ICU mortality. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software (version 25; SPSS Inc., Chicago, IL, USA). A significance level of P <0.05 was considered for all analyses.
Results
Sixty-eight adults were enrolled, with a crude mortality in pre- and post-pandemic periods being 25.5% and 10.0% (P=0.200), respectively. Twenty (29.4%) were respiratory and 29 (41.2%) were soft tissue infections. The incidence had valleys (<1/100,000) in 2020 and 2021 and peaks (>4/100,000 inhabitants) in 2014, 2019, and 2023. Pre-pandemic patients were significantly younger (median: 58.0 vs. 67.5 years, P <0.050), had lower Charlson scores (median: 0 vs. 2, P=0.009), and required more renal replacement therapy (48.9% vs. 15.0%, P=0.013). Emm1 type was the most frequent isolated strain, with the M1uk lineage being represented in 6 out of 7 Emm1 isolates in post-pandemic period. M1uk-infected patients were older (median: 67.0 vs. 50.0 years, P=0.073) but mortality was similar. Most patients (86.6%) received β-lactams plus clindamycin. Interestingly, time to clindamycin administration was earlier (median: 1 h vs. 24 h; P <0.050) in the post-pandemic period with a 5-fold increase in ICU mortality (5.6% to 26.5%, OR=6.14, 95% CI: 0.74 to 50.85; P=0.090) among those adults who did not receive clindamycin in the emergency department.
Conclusions
The incidence of iGAS infections requiring ICU admission showed no significant increase post-Coronavirus Disease-19 pandemic. The highly toxigenic M1uk strain became predominant, but it was not associated with worse mortality among adult ICU patients.
dc.format
application/pdf
dc.relation
Journal of Intensive Medicine;5(4)
dc.relation
https://doi.org/10.1016/j.jointm.2025.06.001
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Malalties bacterianes - Epidemiologia
dc.subject
Unitats de cures intensives
dc.subject
Streptococcus pyogenes
dc.subject
Malalties bacterianes - Tractament
dc.subject
Medicaments antiinfecciosos - Ús terapèutic
dc.subject
HEALTH CARE::Health Care Facilities, Manpower, and Services::Health Facilities::Hospital Units::Intensive Care Units
dc.subject
ORGANISMS::Bacteria::Firmicutes::Lactobacillales::Streptococcaceae::Streptococcus::Streptococcus pyogenes
dc.subject
DISEASES::Bacterial Infections and Mycoses::Bacterial Infections
dc.subject
Other subheadings::Other subheadings::Other subheadings::/epidemiology
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ATENCIÓN DE SALUD::instalaciones, servicios y personal de asistencia sanitaria::centros sanitarios::unidades hospitalarias::unidades de cuidados intensivos
dc.subject
ORGANISMOS::Bacteria::Firmicutes::Lactobacillales::Streptococcaceae::Streptococcus::Streptococcus pyogenes
dc.subject
ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Severe invasive Streptococcus pyogenes infections: A 15-year observational study with molecular characterization of isolates among intensive care adults
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion